Perhaps most reassuring about semaglutide’s cardiovascular benefits is their durability over time. The protection against major adverse cardiac events persisted throughout the study’s follow ...

Ozempic and Wegovy, which are based on the active ingredient semaglutide, may provide notable advantages for cardiac health, including a decreased risk of stroke or heart attack, irrespective of ...

At just three months, before dose titration was over, participants on semaglutide had a noted decreased risk for stroke, heart attack, or cardiovascular death, with additional benefits at six months.

The anti-obesity medication semaglutide may help to prevent heart attacks and other major adverse cardiac events among overweight people who have cardiovascular disease, whether or not they also ...

In SELECT, semaglutide showed a 20% reduction in major adverse cardiovascular events (MACE) – including cardiovascular death, non-fatal heart attack, or non-fatal stroke – with the benefits ...

Semaglutide boosts heart health, weight loss but may lead to gut problems. ... Untangling different health benefits resulting from semaglutide from those resulting from weight loss can be difficult.

The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who ...

A new meta-analysis confirms that semaglutide drugs like Ozempic are not only effective for weight loss, but can also protect the heart. However, certain doses and delivery systems can lead to ...

Among patients who have obesity-related heart failure with preserved ejection fraction (HFpEF), once-weekly semaglutide 2.4 mg (Wegovy; Novo Nordisk) induces greater weight loss in women than in men ...

Semaglutide may offer additional benefits for people already taking statins. Broader heart benefits could mean more people will want to take Ozempic and Wegovy. But for that to happen, Wong says ...

Semaglutide’s cardiovascular benefits remain effective in individuals with impaired kidney function, offering heart protection even with reduced renal health.

Treatment was discontinued more often in the semaglutide group, primarily driven by gastrointestinal disorders (14.7% vs 9.0% in the heart failure groups; and 17.2% vs 7.9% in non-heart failure ...